Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Mind Medicine Announces $50 Million Bought Deal Financing Da

<< Previous

Bullboard Posts

Next >>

Comment by Polaris570on Dec 14, 2020 8:53pm

291 Views

Post# 32106098

RE:Mind Medicine Announces $50 Million Bought Deal Financing Da

This doesn"t look good for share holders especially at that much of a discount. Dilution of shares is never good for the investers unless this is going to be used wisely for the future growth of the company.

<< Previous

Bullboard Posts

Next >>

Understanding tax loss season and the “Santa Claus rally”